Results of a 2021 French National Survey on Management of Patients with Advanced Stage Epithelial Ovarian Cancer

Background: The aim of this study was to assess current French practices in the management of patients with advanced epithelial ovarian cancer. Method: a 58-question electronic survey was distributed anonymously to the members of the SFOG (French Society of Gynaecological Oncology), GINECO-ARCAGY (N...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Leonor Drouin, Benedetta Guani, Vincent Balaya, Henri Azaïs, Sarah Betrian, Pierre-Adrien Bolze, Yohann Dabi, Yohan Kerbage, Claire Sanson, François Zaccarini, Patrice Mathevet, Fabrice Lécuru, Fréderic Guyon, Cherif Akladios, Sofiane Bendifallah, Elise Deluche, on behalf of the SFOG Campus (Young of French Society of Gynecological Oncology)
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	ovarian carcinoma practice management survey surgical oncology medical oncology Medicine R
Acceso en línea:	https://doaj.org/article/26d6e92d4b844d31ab473c661b67e30a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:26d6e92d4b844d31ab473c661b67e30a
record_format	dspace
spelling	oai:doaj.org-article:26d6e92d4b844d31ab473c661b67e30a2021-11-11T17:30:10ZResults of a 2021 French National Survey on Management of Patients with Advanced Stage Epithelial Ovarian Cancer10.3390/jcm102148292077-0383https://doaj.org/article/26d6e92d4b844d31ab473c661b67e30a2021-10-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/21/4829https://doaj.org/toc/2077-0383Background: The aim of this study was to assess current French practices in the management of patients with advanced epithelial ovarian cancer. Method: a 58-question electronic survey was distributed anonymously to the members of the SFOG (French Society of Gynaecological Oncology), GINECO-ARCAGY (National Investigators Group for Ovarian and Breast Cancer Studies in France) and FRANCOGYN (French research group in oncological and gynaecological surgery). Initial diagnostic workup and staging, pathological data, surgical data, treatments and follow-up strategies were assessed. Results: a total of 107 participants responded to emailed surveys. Most of the respondents were obstetrician-gynaecologists (37.4%), surgical oncologists (34.6%) and medical oncologists (17.8%). According to most (76.8%) participants, less than 50% of patients were eligible for primary debulking surgery (PDS). The LION study criteria were applied in 69.5% of cases during PDS and 39% after chemotherapy. The timing of BRCA testing was very heterogeneous and ranged from 1 to 6 months. The use of bevacizumab as an adjuvant schedule was lower in cases of no residual disease (for 54.5% of respondents) compared to cases of residual disease (for 63.6% of respondents). In cases of BRCA1-2 mutations, olaparib was given by 75.8–84.8% of respondents, whereas niraparib was given in cases of BRCA wild-type diseases. Conclusion: this survey provides an extensive and a unique review of current French practices in the management of patients with advanced epithelial ovarian cancer in 2021.Leonor DrouinBenedetta GuaniVincent BalayaHenri AzaïsSarah BetrianPierre-Adrien BolzeYohann DabiYohan KerbageClaire SansonFrançois ZaccariniPatrice MathevetFabrice LécuruFréderic GuyonCherif AkladiosSofiane BendifallahElise Delucheon behalf of the SFOG Campus (Young of French Society of Gynecological Oncology)MDPI AGarticleovarian carcinomapractice managementsurveysurgical oncologymedical oncologyMedicineRENJournal of Clinical Medicine, Vol 10, Iss 4829, p 4829 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	ovarian carcinoma practice management survey surgical oncology medical oncology Medicine R
spellingShingle	ovarian carcinoma practice management survey surgical oncology medical oncology Medicine R Leonor Drouin Benedetta Guani Vincent Balaya Henri Azaïs Sarah Betrian Pierre-Adrien Bolze Yohann Dabi Yohan Kerbage Claire Sanson François Zaccarini Patrice Mathevet Fabrice Lécuru Fréderic Guyon Cherif Akladios Sofiane Bendifallah Elise Deluche on behalf of the SFOG Campus (Young of French Society of Gynecological Oncology) Results of a 2021 French National Survey on Management of Patients with Advanced Stage Epithelial Ovarian Cancer
description	Background: The aim of this study was to assess current French practices in the management of patients with advanced epithelial ovarian cancer. Method: a 58-question electronic survey was distributed anonymously to the members of the SFOG (French Society of Gynaecological Oncology), GINECO-ARCAGY (National Investigators Group for Ovarian and Breast Cancer Studies in France) and FRANCOGYN (French research group in oncological and gynaecological surgery). Initial diagnostic workup and staging, pathological data, surgical data, treatments and follow-up strategies were assessed. Results: a total of 107 participants responded to emailed surveys. Most of the respondents were obstetrician-gynaecologists (37.4%), surgical oncologists (34.6%) and medical oncologists (17.8%). According to most (76.8%) participants, less than 50% of patients were eligible for primary debulking surgery (PDS). The LION study criteria were applied in 69.5% of cases during PDS and 39% after chemotherapy. The timing of BRCA testing was very heterogeneous and ranged from 1 to 6 months. The use of bevacizumab as an adjuvant schedule was lower in cases of no residual disease (for 54.5% of respondents) compared to cases of residual disease (for 63.6% of respondents). In cases of BRCA1-2 mutations, olaparib was given by 75.8–84.8% of respondents, whereas niraparib was given in cases of BRCA wild-type diseases. Conclusion: this survey provides an extensive and a unique review of current French practices in the management of patients with advanced epithelial ovarian cancer in 2021.
format	article
author	Leonor Drouin Benedetta Guani Vincent Balaya Henri Azaïs Sarah Betrian Pierre-Adrien Bolze Yohann Dabi Yohan Kerbage Claire Sanson François Zaccarini Patrice Mathevet Fabrice Lécuru Fréderic Guyon Cherif Akladios Sofiane Bendifallah Elise Deluche on behalf of the SFOG Campus (Young of French Society of Gynecological Oncology)
author_facet	Leonor Drouin Benedetta Guani Vincent Balaya Henri Azaïs Sarah Betrian Pierre-Adrien Bolze Yohann Dabi Yohan Kerbage Claire Sanson François Zaccarini Patrice Mathevet Fabrice Lécuru Fréderic Guyon Cherif Akladios Sofiane Bendifallah Elise Deluche on behalf of the SFOG Campus (Young of French Society of Gynecological Oncology)
author_sort	Leonor Drouin
title	Results of a 2021 French National Survey on Management of Patients with Advanced Stage Epithelial Ovarian Cancer
title_short	Results of a 2021 French National Survey on Management of Patients with Advanced Stage Epithelial Ovarian Cancer
title_full	Results of a 2021 French National Survey on Management of Patients with Advanced Stage Epithelial Ovarian Cancer
title_fullStr	Results of a 2021 French National Survey on Management of Patients with Advanced Stage Epithelial Ovarian Cancer
title_full_unstemmed	Results of a 2021 French National Survey on Management of Patients with Advanced Stage Epithelial Ovarian Cancer
title_sort	results of a 2021 french national survey on management of patients with advanced stage epithelial ovarian cancer
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/26d6e92d4b844d31ab473c661b67e30a
work_keys_str_mv	AT leonordrouin resultsofa2021frenchnationalsurveyonmanagementofpatientswithadvancedstageepithelialovariancancer AT benedettaguani resultsofa2021frenchnationalsurveyonmanagementofpatientswithadvancedstageepithelialovariancancer AT vincentbalaya resultsofa2021frenchnationalsurveyonmanagementofpatientswithadvancedstageepithelialovariancancer AT henriazais resultsofa2021frenchnationalsurveyonmanagementofpatientswithadvancedstageepithelialovariancancer AT sarahbetrian resultsofa2021frenchnationalsurveyonmanagementofpatientswithadvancedstageepithelialovariancancer AT pierreadrienbolze resultsofa2021frenchnationalsurveyonmanagementofpatientswithadvancedstageepithelialovariancancer AT yohanndabi resultsofa2021frenchnationalsurveyonmanagementofpatientswithadvancedstageepithelialovariancancer AT yohankerbage resultsofa2021frenchnationalsurveyonmanagementofpatientswithadvancedstageepithelialovariancancer AT clairesanson resultsofa2021frenchnationalsurveyonmanagementofpatientswithadvancedstageepithelialovariancancer AT francoiszaccarini resultsofa2021frenchnationalsurveyonmanagementofpatientswithadvancedstageepithelialovariancancer AT patricemathevet resultsofa2021frenchnationalsurveyonmanagementofpatientswithadvancedstageepithelialovariancancer AT fabricelecuru resultsofa2021frenchnationalsurveyonmanagementofpatientswithadvancedstageepithelialovariancancer AT fredericguyon resultsofa2021frenchnationalsurveyonmanagementofpatientswithadvancedstageepithelialovariancancer AT cherifakladios resultsofa2021frenchnationalsurveyonmanagementofpatientswithadvancedstageepithelialovariancancer AT sofianebendifallah resultsofa2021frenchnationalsurveyonmanagementofpatientswithadvancedstageepithelialovariancancer AT elisedeluche resultsofa2021frenchnationalsurveyonmanagementofpatientswithadvancedstageepithelialovariancancer AT onbehalfofthesfogcampusyoungoffrenchsocietyofgynecologicaloncology resultsofa2021frenchnationalsurveyonmanagementofpatientswithadvancedstageepithelialovariancancer
_version_	1718432050920292352

Results of a 2021 French National Survey on Management of Patients with Advanced Stage Epithelial Ovarian Cancer

Ejemplares similares